PD-1抑制剂卡瑞利珠单抗治疗晚期食管鳞癌患者的临床疗效及安全性

目的:探究卡瑞利珠单抗治疗晚期食管鳞癌患者的临床疗效及安全性。方法:回顾性收集62例晚期食管鳞癌患者,根据治疗方案分对照组32例,实验组30例,对照组应用多西他赛静脉化疗,实验组应用多西他赛联合卡瑞利珠单抗化疗。观察两组患者治疗期间疗效及不良反应发生情况,疗效评估参考RECIST 1.1标准,不良反应参考CTCAE4.0标准。结果:共计62例患者纳入分析,在基本资料上两组数据有可比性（P＞0.05）,疗效分析两组在完全缓解及部分缓解上差异无统计学意义,在疾病稳定和进展上(P<0.05),差异有统计学意义,就缓解率来讲,实验组客观缓解率（23.33%）、疾病控制率（76.66%）均高于对照组客观缓解率（15.62%）、疾病控制率（40.62%）。实验组最常见的不良反应为甲状腺功能减退、发热、乏力、胃肠道反应、贫血等。结论:晚期食管鳞癌患者应用卡瑞利珠单抗治疗有一定疗效,且不良反应耐受,值得进一步研究。

Efficacy and safety analysis of PD-1 inhibitor camrelizumab in treatment of advanced esophageal squamous carcinoma

Objective:To explore the efficacy and safety analysis of PD-1 inhibitor camrelizumab in treatment of advanced esophageal squamous carcinoma.Methods:We collected patients with advanced esophageal squamous carcinoma who used to hospitalize in our hospital from July 2019 to August 2020.The control group intravenously received docetaxel.The experimental group has intravenously received docetaxel as well as camrelizumab.Then we observed the efficacy and safety of the two groups,Response Evaluation Criteria in Solid Tumors,version 1.1 and Common Terminology Criteria for Adverse Events,version 4．0 were used to evaluate efficacy and adverse effects.Results:A total of 62 patients were included in this analysis.The basic items between the two groups were comparable(P＞0.05).As for the efficacy,there was no sense between the two groups in complete response(CR) and partial response(PR)(P＞0.05).However,stable disease(SD) and progressive disease(PD) had statistical differences(P<0.05).The objective respondse rate and the disease control rate of the control group is 15.62% and 40.62%,which was 23.33% and 76.66% in the experimental group.The most common toxicity in esperimental group reactions were hypothyroidism,fervescence,hypodynamicy,gastroenteric reaction,anemia.Conclusion:The efficacy and safety of camrelizumab used in experimental squamous carcinoma are affirmatory,which is worth to be promoted in the future.